ACDP TSE Subgroup: Updated position statement on occurrence of vCJD and prevalence of infection in the UK
![ACDP TSE Subgroup: Updated position statement on occurrence of vCJD and prevalence of infection in the UK](https://clinicalvirology.org/wp-content/uploads/2022/07/pexels-chokniti-khongchum-2280571-400x267.jpg 100w, https://clinicalvirology.org/wp-content/uploads/2022/07/pexels-chokniti-khongchum-2280571-600x401.jpg 300w, https://clinicalvirology.org/wp-content/uploads/2022/07/pexels-chokniti-khongchum-2280571-800x534.jpg 500w, https://clinicalvirology.org/wp-content/uploads/2022/07/pexels-chokniti-khongchum-2280571-1000x668.jpg 700w, https://clinicalvirology.org/wp-content/uploads/2022/07/pexels-chokniti-khongchum-2280571-1200x801.jpg 900w, https://clinicalvirology.org/wp-content/uploads/2022/07/pexels-chokniti-khongchum-2280571-1400x935.jpg 1100w, https://clinicalvirology.org/wp-content/uploads/2022/07/pexels-chokniti-khongchum-2280571.jpg 1138w)
Advisory Committee on Dangerous Pathogens TSE Subgroup: Updated position statement on occurrence of vCJD and prevalence of infection in the UK
Advisory Committee on Dangerous Pathogens TSE Subgroup: Updated position statement on occurrence of vCJD and prevalence of infection in the UK
Oct 09, 2024
READ MORE
Aug 28, 2024
READ MORE
Feb 26, 2024
READ MORE